Thank you, Ms. Thompson.
Certainly, I'd be pleased to do that, because of course it has been an unprecedented situation that we've faced with COVID-19. I think we can say, and I think we all saw, that our government was in action as soon as the pandemic was acknowledged and declared.
Since it began in 2020, there was a full-court press on responding to COVID-19, working with partners to procure vaccines, personal protective equipment, ventilators, masks and gowns, all in an effort to keep Canadians as safe and as healthy as possible. We did establish complementary supply chains from a range of suppliers, and we partnered with Canadian industry to rapidly scale up and retool production capacity, ensuring a reliable domestic supply to serve our needs for the short and long terms. I think we all remember the stories of so many people stepping up to the plate to do their part.
Since July 2021, Canada has maintained a steady supply of vaccines for every eligible person who wants one. Deliveries from international and domestic sources came in consistently and on schedule to meet our needs, so we have now ensured that we have procured a steady supply of life-saving medical supplies in the short and long terms.
I think we should realize that Canada is currently among the top G20 countries for rate of vaccination. Obviously we still need people to get their boosters, but we have enough. We have secured future supply with Moderna and Pfizer that will provide an access to the range of products that's required, including—and you will have no doubt noted this in the news quite recently—the pediatric supply that's so important to keep our children safe as well. Also, of course, as the variants have occurred, we've kept up and ensured that we've received those vaccines as well.
In terms of more recent times, we have secured a supply of 12.6 million doses of the bivalent, the BA.4 and BA.5 vaccines, to be delivered this year. So far, some 7.8 million bivalent doses have been delivered. We've also secured a supply of a number of therapeutics—you may have heard of Paxlovid—so that specifically if people have respiratory symptoms they can be provided with a prescription.
There are actually some nine different therapeutics that we have acquired, and that was obviously at the behest of the Public Health Agency of Canada. As of October 2022, PSPC has been able to secure orders for more than 2.27 million treatment courses for use in Canada of these nine different therapeutics. Actually, I was interested to learn that these are expensive medications. They vary in cost from $900 to up to $3,000 for a course of treatment.
We have been on top of the situation every step of the way to the extent possible and, of course, we need to remain vigilant going forward.